

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box, 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/070,209 07/12/2002 Masahiro Sakanaka 57094 (71526) 9390 EXAMINER 21874 7590 10/22/2003 EDWARDS & ANGELL, LLP PATTEN, PATRICIA A P.O. BOX 9169 ART UNIT PAPER NUMBER BOSTON, MA 02209 1654

DATE MAILED: 10/22/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
A.		10/070,209	SAKANAKA ET AL.
	Office Action Summary	Examiner	Art Unit
		Patricia A Patten	1654
Period fo	The MAILING DATE of this communication ap or Reply	opears on the cover sheet with	the correspondence address
THE - Exte after - If the - If NO - Failu - Any	IORTENED STATUTORY PERIOD FOR REPI MAILING DATE OF THIS COMMUNICATION. ensions of time may be available under the provisions of 37 CFR 1 or SIX (6) MONTHS from the mailing date of this communication. esperiod for reply specified above is less than thirty (30) days, a report of the provision of	. 136(a). In no event, however, may a reply ply within the statutory minimum of thirty (3 d will apply and will expire SIX (6) MONTH: tte, cause the application to become ABAN	y be timely filed 10) days will be considered timely. S from the mailing date of this communication. DONED (35 U.S.C. § 133).
1)⊠	Responsive to communication(s) filed on 15	September 2003 .	
2a) <u></u> ☐	This action is FINAL . 2b)⊠ T	his action is non-final.	
3)☐ Disposit	Since this application is in condition for allow closed in accordance with the practice unde ion of Claims		
4)⊠	Claim(s) 94-96 is/are pending in the applicat	ion.	
	4a) Of the above claim(s) is/are withdra	awn from consideration.	•
5)[Claim(s) is/are allowed.		
6)⊠	Claim(s) <u>94-96</u> is/are rejected.		
7)	Claim(s) is/are objected to.		
8)[Claim(s) are subject to restriction and/	or election requirement.	
Applicat	ion Papers	•	
9)⊠	The specification is objected to by the Examin	ier.	
10)⊠	The drawing(s) filed on 28 February 2000 is/ar	re: a)⊠ accepted or b)⊡ object	ed to by the Examiner.
	Applicant may not request that any objection to t		
11)	The proposed drawing correction filed on	is: a)□ approved b)□ disa	approved by the Examiner.
	If approved, corrected drawings are required in re	• •	
,	The oath or declaration is objected to by the E	xaminer.	
Priority	under 35 U.S.C. §§ 119 and 120		
13)⊠	Acknowledgment is made of a claim for foreig	gn priority under 35 U.S.C. § 1	19(a)-(d) or (f).
a)	⊠ All b) Some * c) None of:		
	1. Certified copies of the priority documer	nts have been received.	
	2. Certified copies of the priority documer	nts have been received in App	lication No
* (3. Copies of the certified copies of the pri- application from the International B See the attached detailed Office action for a lis	Bureau (PCT Rule 17.2(a)).	
_	Acknowledgment is made of a claim for domes	·	
•	a) The translation of the foreign language p		
	Acknowledgment is made of a claim for domes		
Attachmer		, , ,	-
2) Notice	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Info	nmary (PTO-413) Paper No(s) rmal Patent Application (PTO-152)

Art Unit: 1654

DETAILED ACTION

Page 2

Claims 94-96 are pending in the application.

Applicant's election of Group VII as well as the species of 'ginseng components' in the response of 9/12/03 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Claims 94-96 were examined on the merits.

Specification

The disclosure is objected to because it does not appear that the disclosure contains a Brief Description of the Drawings. Applicants are asked to submit a Brief Description of the Drawings in accordance with 37 CFR 1.74 which does not introduce new matter into the disclosure.

This application does not contain an abstract of the disclosure as required by 37 CFR 1.72(b). An abstract on a separate sheet is required.

Priority

This lacks the necessary reference to the prior application. A statement reading "This is a 371 of Application No. PCT/JP00/04102, filed 6/22/2000 which claims priority to JP 11-24 3378 filed in Japan on 08/30/1999" should be entered following the title of the invention or as the first sentence of the specification. Also, the current status of the parent nonprovisional application(s) should be included.

Information Disclosure Statement

The IDS submitted 2/28/02 was accompanied by a PTO-1449 form. However, this form did not include the title of the references, or the authors. In order for the Examiner to initial this form and consider all of the references, Applicants are asked to submit a new PTO-1449 which includes the titles of the references as well as the authors. This is necessary in order to properly bibliograph the documents upon printing.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Art Unit: 1654

Claims 94-96 are rejected under 35 U.S.C. 102(b) as being anticipated by Arikhbaieff (FR 2,648,046). Claims 94-96 are drawn to a method for treating a mammal suffering from or susceptible to a disease causing apoptosis or apoptosis-like cell death with ginseng components. Claims are further drawn to wherein the ginseng components comprise non-saponin fractions for example, and wherein the ginseng is red ginseng.

Arikhbaieff (FR 2,648,046) disclosed a method for enhancing immune function via the administration of a beverage which included red ginseng comprising saponins (English Abstract). The term 'disease' was given its broadest interpretation, and it is deemed that immune dysfunction is a 'disease'. Because the only step in the method is administration of a composition comprising a ginseng component, it is deemed that administration of the composition disclosed by Arikhbaieff would have inherently performed this mechanism because it is the same composition given to the same group of patients. Further, it is pointed out that the phrase '...or susceptible to a disease causing apoptosis' can be drawn to *anyone*, because anyone is *susceptible* to diseases which cause apoptosis.

No Claims are allowed.

Art Unit: 1654

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia A Patten whose telephone number is (703) 308-1189. The examiner can normally be reached on 8:30am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on (703) 306-3220. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Patricia A Patten Examiner Art Unit 1654

PATRICIA PATTEN